ATOMIC (Academic Thoracic Oncology Medical Investigators Consortium), met at the IASLC 2023 Targeted Therapies of Lung Cancer symposium in February in Santa Monica.
Continue readingContact Us: 1-518-583-0095 
We’re Hiring… Join Our Team!
AGICC Investigator’s Meeting – Investigators Meet at ASCO GI For the First Time Since Covid
AGICC (Academic GI Cancer Consortium) met in person for an Investigator’s Meeting during the recent GI-ASCO 2023 Symposium in San Francisco. This coming year the AGICC group will continue to explore GI oncology trials in partnership with pharmaceutical companies.
Continue readingAURIC Investigator’s Meeting – Successful First Meeting of Newly Formed Group
The Academic Urology Research Investigators Consortium met for an initial Investigator’s Meeting during the recent GU-ASCO 2023 in San Francisco to explore new studies for the coming year. The group’s primary focus is to partner with pharmaceutical companies looking to explore novel genitourinary oncology trials.
Continue readingManagement of toxicities with novel systemic therapies in UC
AURIC Director Thomas Flaig, MD, of the University of Colorado Anschutz Medical Campus in Aurora, Colorado, provides an overview of the management of toxicities with novel systemic therapies in patients with urothelial carcinoma (UC), highlighting the use of antibody-drug conjugates in advanced disease.
Continue readingInternational Thoracic Oncology Experts – ESMO Panel Discussion
ATOMIC Director Ross Camidge MD, PhD, draws out novel opinions across the field of thoracic oncology from a panel of international experts discussing their favorite ESMO abstracts from 2022.
Continue readingIndustry News: Brain MRI surveillance needed for TKl-treated ALK or ROS7-positive NSCLC
Retrospective data showed how common central nervous system metastases are among patients with non-small cell lung cancer and ALK or ROS1 alterations who have been treated with tyrosine kinase inhibitors.
Continue readingPharmaVoice Interview with Dr. Peter Kabos, Director of the Academic Breast Cancer Consortium (ABRCC)
Watch this PharmaVoice One on One video interview to learn more about the latest in breast cancer research from Dr. Peter Kabos, Director of the Academic Breast Cancer Consortium and Assistant Professor in the Division of Medical Oncology at University of Colorado Cancer Center.
Continue readingPharmaVoice Interview with Dr. D. Ross Camidge, Director of the Academic Thoracic Oncology Medical Investigators Consortium (ATOMIC)
Watch the PharmaVoice One on One video interview below to learn more about the latest in Thoracic Oncology research from Dr. D. Ross Camidge, Director of the Academic Thoracic Oncology Medical Investigators Consortium and Director of Thoracic Oncology at the University of Colorado.
Continue readingPharmaVoice Interview with Dr. Wells Messersmith, Director of the Academic GI Cancer Consortium (AGICC)
Watch the PharmaVoice One on One video interview below to learn more about the latest in Gastrointestinal Cancer research from Dr. Wells Messersmith, Director of the Academic GI Cancer Consortium and Division Head of Medical Oncology at the University of Colorado Cancer Center.
Continue readingWhat’s New in Breast Cancer Research and Treatment?
Criterium’s Academic Breast Cancer Consortium (ABRCC) is comprised of 15 renowned academic and community sites in North America, conducting translational research in Breast Cancer studies for major pharmaceutical companies who are working on the most current clinical trials for advanced treatments of breast cancer. While 2020 was a year dominated by COVID-19 news and tragedy, breast cancer research and breakthroughs can’t wait for COVID to “go away” – and research in this area continues on full-speed. Our ABRCC researchers reflect on 2020 and look ahead to 2021 with renewed hope.
Continue reading